2012
Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping
Schwartz GF, Bartelink H, Burstein HJ, Cady B, Cataliotti L, Fentiman IS, Holland R, Hughes KS, Masood S, McCormick B, Palazzo JA, Pressman PI, Reis‐Filho J, Pusztai L, Rutgers EJ, Seidman AD, Solin LJ, Sparano JA. Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping. The Breast Journal 2012, 18: 303-311. PMID: 22759093, DOI: 10.1111/j.1524-4741.2012.01264.x.Peer-Reviewed Original ResearchConceptsStage I carcinomaAdjuvant therapyBreast cancerGene prognostic signaturePatient ageTumor sizeImmunohistochemical markersIndividual patientsConsensus conferencePrognostic signatureSteroid hormonesMolecular profilingNottingham indexMolecular phenotypingPatientsCarcinomaTherapyCancerBreastPrognosisPart of decisionHormone
2010
Stability of estrogen receptor status in breast carcinoma
Gong Y, Han EY, Guo M, Pusztai L, Sneige N. Stability of estrogen receptor status in breast carcinoma. Cancer 2010, 117: 705-713. PMID: 20939012, DOI: 10.1002/cncr.25506.Peer-Reviewed Original ResearchConceptsER statusBreast carcinomaEndocrine therapyMetastatic sitesPrimary tumorMetastatic tumorsMetastatic breast carcinomaEstrogen receptor statusER discordanceDisease courseReceptor statusSystemic therapyClinical courseER expressionER testingClinical managementNegative conversionER assaysDiscordant casesCarcinomaPositive conversionTumorsPatientsMetastasisTherapy
2007
Primary systemic chemotherapy of invasive lobular carcinoma of the breast
Katz A, Saad ED, Porter P, Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. The Lancet Oncology 2007, 8: 55-62. PMID: 17196511, DOI: 10.1016/s1470-2045(06)71011-7.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaInvasive ductal carcinomaLobular carcinomaSystemic chemotherapyDuctal carcinomaAdjuvant systemic chemotherapyPrimary systemic chemotherapyUse of chemotherapyFrequent histological typeProspective clinical trialsDistinct clinical entityAdjuvant chemotherapyRandomised trialsHistological typeClinical entityBreast diseaseClinical trialsBreast cancerEstrogen receptorChemotherapyInsufficient evidencePrevention strategiesCarcinomaBest treatmentLow grade
2004
Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma
Gonzalez‐Angulo A, Krishnamurthy S, Yamamura Y, Broglio KR, Pusztai L, Buzdar AU, Hortobagyi GN, Esteva FJ. Lack of association between amplification of her‐2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004, 101: 258-263. PMID: 15241821, DOI: 10.1002/cncr.20348.Peer-Reviewed Original ResearchConceptsEarly-stage breast carcinomaBreast carcinomaTumor specimensPathologic responseStage II breast carcinomaAJCC stage IIMedian patient ageStage III diseasePathologic complete responseOverall survival rateLack of associationGene amplificationPreoperative chemotherapyRecurrent diseaseComplete responsePatient agePatientsCarcinomaSurvival rateTissue specimensStage IITaxanesHormone receptorsTumorsDiseaseThe Role of Sigma Receptor in Breast Cancer
Pusztai L. The Role of Sigma Receptor in Breast Cancer. 2004 DOI: 10.21236/ada425685.Peer-Reviewed Original ResearchBreast cancerReceptor mRNA expressionBreast cancer cell linesHuman breast cancerSigma-1 receptorCancer cell linesDuctal carcinomaInvasive cancerNormal breastSigma receptorsSIG 1Sigma ligandsMRNA expressionCancerCell linesReceptorsHuman tissuesCell growthExpressionChemotherapyCarcinomaHyperplasiaBreastPharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM, Esteva FJ, Symmans WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL, Drake RR, Vlahou A. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004, 100: 1814-1822. PMID: 15112261, DOI: 10.1002/cncr.20203.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBiopsy, NeedleBreast NeoplasmsCase-Control StudiesChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFemaleFluorouracilHumansMastectomyMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelPostoperative CarePreoperative CareProteomicsRisk AssessmentSensitivity and SpecificitySurvival AnalysisTreatment OutcomeConceptsBreast carcinomaHealthy womenPreoperative chemotherapyFinal tumor responseSubset of patientsDay 3 posttreatmentAdjuvant chemotherapyPostoperative chemotherapyCyclophosphamide chemotherapyFAC chemotherapyMicrometastatic diseasePaclitaxel chemotherapyNormal womenTumor responsePlasma profilesHealthy volunteersChemotherapyPatientsStage ICarcinomaDay 0Single courseWomenPlasma samplesCandidate markersCorrelation between response to neoadjuvant chemotherapy (NACT) with single agent taxanes and HER-2 gene amplification in patients with breast carcinoma
Gonzalez-Angulo A, Krishnamurthy S, Yamamura Y, Pusztai L, Buzdar A, Hortobagyi G, Esteva F. Correlation between response to neoadjuvant chemotherapy (NACT) with single agent taxanes and HER-2 gene amplification in patients with breast carcinoma. European Journal Of Cancer Supplements 2004, 2: 70. DOI: 10.1016/s1359-6349(04)90651-9.Peer-Reviewed Original Research